To produce messenger RNA, the spliceosome excises introns from precursor (pre)-mRNA and splices the flanking exons. To establish fidelity, the spliceosome discriminates against aberrant introns, but current understanding of such fidelity mechanisms is limited. Here we show that an ATP-dependent activity represses formation of mRNA from aberrant intermediates having mutations in any of the intronic consensus sequences. This proofreading activity is disabled by mutations that impair the ATPase or RNA unwindase activity of Prp22p, a conserved spliceosomal DExD/H-box ATPase. Further, cold-sensitive prp22 mutants permit aberrant mRNA formation from a mutated 3¢ splice-site intermediate in vivo. We conclude that Prp22p generally represses splicing of aberrant intermediates, in addition to its known ATP-dependent role in promoting release of genuine mRNA. This dual function for Prp22p validates a general model in which fidelity can be enhanced by a DExD/H-box ATPase.
Nuclear pre-mRNA introns are defined by conserved sequences at the 5¢ splice site, the branch site and the 3¢ splice site 1 . These sequences determine the sites of the two chemical reactions in splicing 1 . First, the 2¢ hydroxyl of the branch-site adenosine attacks the 5¢ splice site, forming a lariat intermediate and liberating the 5¢ exon. Second, the 3¢ hydroxyl of the 5¢ exon attacks the 3¢ splice site, excising the intron and ligating the exons. The consensus sequences also enable fidelity mechanisms that discriminate against incorrect splice sites, which differ from correct ones in position, sequence or both.
Splicing is catalyzed by the spliceosome 1 , a ribonucleoprotein machine composed of more than 100 proteins and five small nuclear RNAs (snRNAs). The snRNAs recognize intronic consensus sequences 1 and may participate directly in catalysis 2 . These functions require snRNA rearrangements 3 that are promoted by members of the DExD/H-box ATPase family 4 , which bind ATP to associate with RNA and/or hydrolyze ATP to dissociate RNA-RNA interactions, RNAprotein interactions or both.
A pioneering genetic study 5 discovered that the fidelity of branchsite recognition is promoted by the DExD/H-box ATPase Prp16p, which also promotes rearrangement of the spliceosome after 5¢ splicesite cleavage 6 . prp16 mutants increase the abundance of aberrant branch-site intermediates, thereby increasing the abundance of aberrant mRNA. Because these mutants hydrolyze ATP inefficiently 5 , it was proposed 5, 7 that Prp16p enhances the fidelity of branchsite recognition by a kinetic proofreading mechanism 8, 9 in which Prp16p-and ATP-dependent rejection competes with splicing. Subsequent genetic studies have identified additional factors that promote the fidelity of intron recognition [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The activity of these factors can be understood within a general thermodynamic framework in which an aberrant substrate equilibrates between the two catalytic conformations of the spliceosome and a fidelity factor favors the conformation that is inactive for the aberrant substrate species 18, 20 .
These genetic advances in understanding fidelity have raised important questions. Given that Prp16p proofreads 5¢ splice-site cleavage 5, 18, 19 , does an ATPase similarly proofread exon ligation? Given the generality of the thermodynamic framework for understanding fidelity funcitons 20 , do additional mechanisms serve fidelity?
Progress has been constrained by the lack of an in vitro assay for the fidelity of splice-site sequence recognition. To investigate fidelity in vitro, we focused on 3¢ splice-site recognition, because it is required for exon ligation (for example, see ref. 21 ) but dispensable for 5¢ splice-site cleavage in budding yeast 22 and in some mammalian introns 23 . Mutations of the 3¢ splice-site consensus (C/UAG) partially impair exon ligation (for example, see ref. 24) , and mutations of the terminal AG severely inhibit exon ligation (for example, see ref. 12) . Many genetic studies [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [25] [26] [27] and one biochemical study 28 have implicated numerous factors in the fidelity of 3¢ splice-site recognition. To date, however, no factor has been shown to enhance fidelity directly at the second catalytic stage of splicing by repressing exon ligation at 3¢ splice sites that deviate from the consensus.
Using a novel in vitro fidelity assay in Saccharomyces cerevisiae, we have discovered a role for ATP in repressing exon ligation at mutated 3¢ splice sites. We have assigned this role to the conserved DExD/Hbox ATPase Prp22p, which is required to release spliced mRNA from the spliceosome 29, 30 . Validating these findings, a prp22 mutant suppresses the exon-ligation defect of a 3¢ splice-site mutant in vivo. We have also found in vitro that Prp22p represses exon ligation of intermediates having an aberrant 5¢ splice site or branch site. Our work suggests that Prp22p generally enhances the fidelity of exon ligation by a proofreading mechanism [7] [8] [9] in which Prp22p-mediated rejection of an intermediate competes with exon ligation. Further, our data underscore the utility of energy in permitting discrimination between correct and nearly-correct substrates 8 .
RESULTS

ATP-dependent repression of mutated 3¢ splice sites
In vivo, splicing intermediates stalled by mutations at the 3¢ splice site are degraded by nuclear or cytoplasmic exonucleases 31, 32 . Cytoplasmic degradation 32 implies that the spliceosome dissociates aberrant intermediates, enhancing fidelity by precluding exon ligation. We set out to establish a biochemical assay for the dissociation of aberrant intermediates. Using budding yeast extract, we assembled spliceosomes on ACT1 pre-mRNA having mutated 3¢ splice sites that stalled spliceosomes before exon ligation 21 (Fig. 1a) . We affinity-purified the stalled spliceosomes at 4 1C; spliceosomes remained stalled at this temperature. Next, we incubated the immobilized spliceosomes at 20 1C in splicing buffer, without extract, in the absence or presence of ATP. Although the spliceosome did not detectably dissociate aberrant intermediates under either condition (data not shown), surprisingly, in the absence of ATP, the spliceosome catalyzed conversion of aberrant intermediates to spliced mRNA and excised intron (Fig. 1b) . Indeed, the spliceosome catalyzed formation of spliced products, 10-to 15-fold above background, from all intermediates containing single mutations of the conserved AG (Fig. 1b) . Depletion of ATP by gel filtration of standard splicing reactions also permitted splicing at a singly mutated 3¢ splice site (data not shown). In contrast, the spliceosome did not catalyze exon ligation from intermediates having double mutations of the AG (Fig. 1c) . These data suggest that aberrant splicing at near-consensus 3¢ splice sites is repressed by an ATP-dependent mechanism.
Indeed, aberrant splicing was repressed efficiently in the presence of ATP, which reduced mRNA abundance to less than two-fold above background (Fig. 1b) . GTP, CTP and UTP also repressed aberrant splicing efficiently (Fig. 1d) , implicating a nonspecific NTPase (see below). In contrast, the addition of budding yeast extract did not repress aberrant splicing (data not shown). Because extract was not required for aberrant splicing, spliceosomes stalled by 3¢ splice-site mutations include all factors required to catalyze exon ligation.
To determine the aberrant exon ligation junction, we sequenced reverse-transcription (RT)-PCR products of the aberrant mRNA and found that aberrant splicing occurred precisely at the mutated 3¢ splice sites (data not shown). This observation is consistent with in vivo findings that an AG is not essential to define a 3¢ splice site in S. cerevisiae (for example, see refs. 12, 21) and Caenorhabditis elegans (for example, see ref. 33) . Note that splicing, albeit at reduced levels, at non-AG sites in vivo (for example, see ref. 12) indicates that fidelity mechanisms do not absolutely repress exon ligation at such aberrant 3¢ splice sites. Although all six substrates with AG point mutations can define a 3¢ splice site, we find in vitro that splicing at such sites is repressed by an ATP-dependent mechanism.
An ATP-dependent fidelity mechanism for exon ligation We distinguished whether the ATP-dependent mechanism generally represses exon ligation or specifically represses exon ligation of mutated substrates, thereby promoting fidelity. To distinguish these possibilities, we developed a general assay for 3¢ splice-site recognition that allowed us to compare splicing at a mutated and a wild-type 3¢ splice site. To trap spliceosomes reversibly at the stage of 3¢ splice-site recognition, we designed a 2¢-O-methyl 'trap' oligonucleotide to anneal with and occlude the 3¢ splice site of ACT1 pre-mRNA 34 (Fig. 2a) . PremRNA annealed to this oligonucleotide was competent for 5¢ splicesite cleavage but not for exon ligation (Fig. 2b) . To permit release from this trap, we designed the trap oligonucleotide with a noncomplementary 5¢ tail to facilitate rapid annealing of a 'release' oligonucleotide and subsequent stripping of the trap oligonucleotide from the 3¢ splice site ( Fig. 2a; compare refs. 35, 36) . After adding excess, unlabeled pre-mRNA to preclude de novo spliceosome assembly on the radiolabeled pre-mRNA, we added the release oligonucleotide, which then liberated the trapped spliceosomes, promoting efficient 3¢ splicesite recognition and exon ligation (Fig. 2b) . These results validated our general strategy for investigating 3¢ splice-site recognition. Using this strategy, we found that ATP inhibits exon ligation at a mutated 3¢ splice site but not at a wild-type 3¢ splice site. After trapping spliceosomes on a wild-type UAG or a mutated UAc substrate (mutation shown in lowercase), we affinity-purified the trapped spliceosomes at 4 1C and then released the trap at 20 1C in splicing buffer in the absence or presence of ATP. In the absence of ATP, spliced products formed at amounts six-fold above background at both the mutated and wild-type 3¢ splice sites (Fig. 2c, lanes 3 and  7) . In contrast, in the presence of ATP, the spliceosome catalyzed splicing only at the wild-type 3¢ splice site; splicing at the mutated 3¢ splice site was undetectable (Fig. 2c, lanes 4 and 8) . Thus, an ATP-dependent mechanism represses splicing at mutated, but not genuine, 3¢ splice sites and therefore represents an authentic mechanism for promoting fidelity in exon ligation.
The ATPase Prp22p represses aberrant 3¢ splice sites The requirement for ATP to repress exon ligation suggested strongly that an ATPase was required for the fidelity of exon ligation. Members of the DExD/H-box family of ATPases 4 were likely candidates, as each ATP-dependent step in splicing requires such an ATPase 3 . Further, our finding that multiple NTPs repress exon ligation at mutated 3¢ splice sites ( Fig. 1d) implicated members of the DEAH-box subfamily of DExD/H-box ATPases, which can use a variety of NTPs 6,37,38 . The strongest candidate was Prp22p, an ATP-dependent RNA unwindase 29, 30, 38 . Prp22p binds the spliceosome before exon ligation 30 , cross-links to the 3¢ splice site 39 and, in an ATP-independent manner, promotes exon ligation at distal 3¢ splice sites 30 . After exon ligation, in an ATP-dependent manner, Prp22p promotes mRNA release from the spliceosome 29, 30 . Further implicating Prp22p, aberrant splicing occurred independently of ATP and extract ( Fig. 1) , indicating that the spliceosome inspects a 3¢ splice site after the ATP-dependent Prp16p stage and after the association of the soluble factors Slu7p, Prp18p and Prp22p 30, 40, 41 . Finally, Prp22p-bound spliceosomes, purified using tandem affinity purification (TAP)-tagged Prp22p, are sufficient to repress mutated 3¢ splice sites in an ATP-dependent manner (data not shown).
We tested Prp22p for a fidelity role and found that mutations in Prp22p compromised 3¢ splice-site fidelity in vitro. To test Prp22p, we purified several Prp22p variants that permit exon ligation at a wildtype 3¢ splice site but impair mRNA release 30, [42] [43] [44] . We added these Prp22p mutants to splicing reactions containing ATP, wild-type extract and a wild-type or mutated (UAc) 3¢ splice-site substrate. In the presence of mutant Prp22p, the spliceosome no longer efficiently repressed splicing at the mutated UAc 3¢ splice site; rather, the spliceosome permitted aberrant formation of excised intron and mRNA (Fig. 3a) . The Prp22p mutants did not generally stimulate exon ligation, because mRNA abundance did not increase in reactions with wild-type substrate (Fig. 3a) ; the abundance of excised intron did increase, owing to retention of the intron on the spliceosome and protection from degradation (for example, see ref. 42 ). These observations indicate that mutations in Prp22p compromise the ATP-dependent mechanism that represses splicing at mutated 3¢ splice sites. The Prp22p variants also permitted formation of longer, aberrant mRNAs from both the wild-type and the UAc 3¢ splice-site substrates ( Fig. 3a; for example, in lanes 4 and 11). RT-PCR and sequence analysis revealed that these mRNAs resulted from splicing at two upstream, cryptic 3¢ splice sites, a UuG at position -21 and a CAu at position -29, indicating that Prp22p mutants can alter the position of 3¢ splice-site cleavage.
We affinity-purified the spliceosomes stalled on the mutated UAc substrate (Fig. 3a) and then assayed for exon ligation in splicing buffer in the presence or absence of ATP. Mutated Prp22p permitted efficient 3¢ splice-site cleavage, ten-fold above background, even in the presence of ATP (Fig. 3b) . Indeed, in the presence of ATP, the mutant proteins repressed aberrant splicing by only two-fold, whereas wild-type Prp22p repressed splicing by nine-fold (Fig. 3b) . In contrast to the Prp22p mutations, the Q423E mutation in the DEAH-box ATPase Prp43p did not compromise the spliceosome's ability to repress exon ligation at the aberrant 3¢ splice site (Fig. 3b) , despite stabilizing the excised intron from a wild-type substrate (data not shown), as expected 45, 46 . Thus, fidelity in exon ligation is compromised by mutations in Prp22p.
Notably, the Prp22p mutations in motif I (K512A) and motif II (D603A) impair ATPase activity 30, 43 , suggesting a requirement for NTP hydrolysis in repressing aberrant splicing. In addition, mutations in motif III (S635A) and motif V (T765A) permit ATP hydrolysis but impair RNA unwinding 42, 44 . Thus, as for mRNA release 29, 30, 42 , repression of aberrant splicing requires both the ATPase and RNA unwindase activities of Prp22p.
To verify these observations, we assayed for aberrant exon ligation in extracts of conditional prp22 mutants 30 altered in domains important for ATP binding and hydrolysis 4 . Specifically, we assembled spliceosomes on the mutated UAc 3¢ splice-site substrate in extracts of the mRNA release-defective mutants prp22-H606A (motif II) and prp22-G810A (motif VI) 42 . We immunoprecipitated the spliceosomes and assayed for exon ligation in splicing buffer in the presence or absence of ATP. Both prp22 mutants permitted splicing, four-fold above background, at the aberrant 3¢ splice site even in the presence of ATP (Fig. 3c) . In contrast, the prp43-Q423N mutant 47 , defective in turnover of the excised intron, did not permit aberrant splicing in the presence of ATP ( Supplementary Fig. 1 online) . These observations verify that Prp22p represses splicing in vitro at aberrant 3¢ splice sites.
To validate our in vitro findings, we assayed for fidelity in vivo in the cold-sensitive mutant strain prp22-R805A (motif VI) 42 , a mutant compromised for fidelity in vitro (data not shown). At 16 1C, this strain accumulated wild-type pre-mRNA and the lariat intermediate and was depleted of mRNA (data not shown), perhaps as an indirect result of a defect in releasing mRNA and recycling essential exon-ligation factors. Therefore, we assayed for aberrant exon ligation at 30 1C, using an ACT1-CUP1 splicing substrate 48 having a pyrimidine-guanine mutation of the 3¢ splice site (gAG). In a wild-type PRP22 strain, this 3¢ splice-site mutation reduced the ratio of mRNA to lariat intermediate by ten-fold, indicating an apparent decrease in the efficiency of exon ligation (Fig. 3d, lanes 1 and 3; compare ref. 13 ). However, in the prp22-R805A mutant strain, the gAG 3¢ splice-site mutation reduced the ratio of mRNA to lariat intermediate by approximately two-fold (Fig. 3d, lanes 2 and 4) , relative to a wildtype substrate. Thus, the prp22 mutant diminished specificity for splicing at a wild-type 3¢ splice site, relative to a mutated 3¢ splice site. Further, whereas splicing at the wild-type 3¢ splice site decreased in the prp22-R805A mutant (Fig. 3d, lanes 1 and 2) , splicing at the mutated gAG 3¢ splice site increased; the ratio of mRNA to lariat intermediate increased by almost five-fold (Fig. 3d, lanes 3 and 4) . To verify that the aberrant mRNA was functional, we assayed for gene expression using the ACT1-CUP1 splicing reporter 48 , which produces Cup1p in a splicing-dependent manner and thereby confers splicing-dependent copper resistance to yeast. With the aberrant gAG 3¢ splice-site reporter, both the prp22-R805A and prp22-G810A mutants 42 showed higher copper resistance than wild-type yeast (Fig. 3e) . Thus, Prp22p inhibits exon ligation at a mutated 3¢ splice site in vivo, confirming our . Wild-type (UAG) or mutated (UAc) pre-mRNA was incubated in wild-type extract supplemented with nothing (-), buffer, wild-type Prp22p (WT) or mutated Prp22p (amino acid mutations are indicated) in standard splicing reactions. In a, these reactions were analyzed directly; in b, the spliceosomes stalled in these reactions were affinity-purified and then treated as in Figure 1b .
Spliceosomes stalled in these reactions were immunoprecipitated and then treated as in Figure 1b . The faster migration of excised lariat intron in this gel is due to the concentration of polyacrylamide. (d) A prp22 mutant is defective in discriminating between a wild-type and a mutated 3¢ splice site in vivo. A wild-type PRP22 (W) or the mutant prp22-R805A (R) strain 42 was transformed with an ACT1-CUP1 splicing reporter 48 having a wild-type UAG or mutated gAG 3¢ splice site. Splicing was analyzed by primer extension. The ratio of mRNA to lariat intermediate is charted as an indicator of the apparent efficiency of exon ligation; the ratio of lariat intermediate to pre-mRNA is charted for comparison. Averages and range of values for two independent experiments are shown. (e) PRP22 mutants are defective in repressing gene expression from an ACT1-CUP1 splicing reporter 48 having the mutated gAG 3¢ splice site. A wild-type PRP22 strain and the mutant strains prp22-R805A (R805A) and prp22-G810A (G810A) were transformed with an ACT1-CUP1 reporter having a wild-type (UAG) or mutated (gAG) 3¢ splice site, then spotted onto copper plates. 
Prp22p represses mutated branch and 5¢ splice sites
To distinguish whether Prp22p represses mutated 3¢ splice sites specifically or aberrant intermediates in general, we tested for a role for Prp22p in repressing branch-site or 5¢ splice-site mutations that impede mRNA formation. The intronic branch site is defined by a UACUAAC sequence (the branch site is underlined) and the 5¢ splice site is defined immediately downstream of the splice site by a GUAUGU sequence. We tested for repression of intermediates containing the mutated branch site UACUAgC (brG) or the mutated 5¢ splice site aUAUGU (G1A). Although the mutated nucleotides participate directly in 5¢ splice-site cleavage, both mutations permit 5¢ splice-site cleavage and impede exon ligation 21, 49, 50 , suggesting that these residues are recognized after 5¢ splice-site cleavage. Allele-specific suppression of the G1A defect suggests that G1 of the 5¢ splice site binds the terminal G of the 3¢ splice site 51 , although this suppression may be indirect 25, 26 . As expected, both mutations permit the formation of intermediates in vitro, although at substantially reduced abundance (Fig 4a) ; mRNA formation was undetectable (Fig. 4a) .
To determine whether the stalled, aberrantly branched intermediates are repressed by a Prp22p-dependent fidelity mechanism, we assembled spliceosomes on pre-mRNAs with a mutated branch site or 5¢ splice site in wild-type extracts that were supplemented with recombinant, wild-type or mutant Prp22p. We affinity-purified the stalled spliceosomes and assayed for exon ligation in the absence or presence of ATP. In the absence of ATP, spliceosomes that were assembled with wild-type Prp22p permitted aberrant splicing of the intermediates with a mutated branch site or 5¢ splice site; these intermediates formed excised introns four-and two-fold above background, respectively (Fig. 4b,c, lane 2) . Because this aberrant splicing required neither ATP nor extract, our data provide the first biochemical evidence that the branched nucleotides are recognized in the second catalytic conformation. This recognition could serve to enhance proofreading of 5¢ splice-site cleavage and to sequester the branch, thereby allowing positioning of the 3¢ splice site 26 .
In the presence of ATP, spliceosomes that were assembled with wildtype Prp22p repressed splicing of aberrantly branched intermediates (Fig. 4b,c, lane 3) . Spliceosomes assembled with mutated Prp22p, in contrast, permitted aberrant splicing even in the presence of ATP (Fig. 4b,c, lanes 6 and 9) . Indeed, mutant Prp22p permitted aberrant splicing in standard splicing reactions, as indicated by the presence of spliced products in purified spliceosomes before further incubation (for example, in lane 4). These data indicate that Prp22p is responsible for the ATP-dependent repression of aberrantly branched intermediates. Demonstrating specificity, spliceosomes assembled with mutated Prp43p did not permit aberrant splicing in the presence of ATP (Fig. 4b,c, lane 15) . To verify the observations with mutated Prp22p, we assembled spliceosomes on the mutated branch-site substrate in prp22 mutant extracts and then assayed for fidelity after affinity purification. These spliceosomes also permit aberrant splicing even in the presence of ATP (data not shown). Thus, Prp22p has a broad role in repressing exon ligation of aberrant intermediates.
DISCUSSION
Although previous work has implicated a number of factors in the fidelity of exon ligation, including U2, U5, U6, the 5¢ splice site, Isy1, Prp8p, Slu7p and Sky1p [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 26, 28 , our work shows a role for Prp22p that is novel in several respects. First, Prp22p is the only ATPase implicated in enhancing the fidelity of the exon-ligation reaction. Second, although Slu7p discriminates against positionally incorrect 3¢ splice sites 28 , it has not been found to discriminate against aberrant 3¢ splice sites that deviate from the consensus, as we have found for Figure 4 An ATP-and Prp22p-dependent mechanism also represses aberrant exon ligation of intermediates having mutations of the branch site or 5¢ splice site. (a) Spliceosomes assembled on ACT1 pre-mRNA substrates with the mutated branch site UACUAgC (brG) or the mutated 5¢ splice site aUAUGU (G1A) catalyzed formation of the intermediates, albeit inefficiently; formation of mRNA was undetectable. Reactions were performed as in Figure 1a . The wild-type (WT) substrate was spliced in parallel for comparison. The 5¢ exon of the G1A substrate is larger than for the other substrates owing to differences in the transcription template (see Methods). (b,c) ATP is required to repress exon ligation of aberrant intermediates having the brG (b) or G1A (c) mutations, and recombinant Prp22p variants compromise this repression. Reactions were performed as in Figure 3b . Affinity purification yielded spliceosomes enriched for lariat intermediate and 5¢ exon, indicating that a substantial fraction of pre-mRNA was not engaged in active spliceosomes. In b, we confirmed by primer extension that the mutated branch was used as the nucleophile in 5¢ splice-site cleavage; further, we confirmed by RT-PCR and sequencing of the mRNA that the genuine 5¢ splice site and 3¢ splice site were used (data not shown). In vivo, the G1A mutated 5¢ splice site of an ACT1-derived reporter is used exclusively as the electrophile in 5¢ splice-site cleavage 21 . Asterisk in c indicates the expected migration of mRNA; low abundance of G1A lariat intermediate precluded visualization of the mRNA.
Prp22p (Figs. 1-3) . Third, although mutations in the invariant loop I of U5 snRNA suppress exon ligation of aberrant intermediates 10 , these mutations establish complementarity between the loop and the first two bases of the 3¢ exon, a complementarity that is not conserved. Thus, it is unclear whether wild-type U5 has a role in the fidelity of exon ligation. In contrast to the U5 suppressor mutations, the prp22 suppressor mutations represent general, loss-of-function mutations 30, 42, 52 , indicating that wild-type Prp22p does have a role in fidelity. Fourth, U2 and sky1 suppressors 12, 15, 17 have not been thoroughly explored. Finally, U6, 5¢ splice site, prp8 and isy1 suppressors seem to act at an earlier stage than prp22 suppressors 18, 19, 26 . Whereas U6, 5¢ splice site, prp8 and isy1 mutants suppress exonligation defects indirectly at the first catalytic stage of splicing 18, 19, 26 , prp22 mutants suppress such defects directly at the second catalytic stage, according to three lines of evidence. First, suppression of exonligation defects by the former mutants correlates with defects in 5¢ splice-site cleavage 18, 19, 26 ; in contrast, suppression of such defects by prp22 mutants (Figs. 3 and 4) correlates with defects in mRNA release [42] [43] [44] 52 . Second, prp22 mutants suppress exon-ligation defects in purified spliceosomes in the absence of budding yeast extract (Figs. 3 and 4) , indicating that prp22 mutants act after the association of exon-ligation factors and after the earlier Prp16p-dependent rearrangement 6, 30, 40, 41 . Third, prp22 mutants can suppress an aberrant substrate that stalls at the exon-ligation stage, because the aberrant, near-consensus UAc 3¢ splice-site intermediate stalls at this stage 6 . Prp22p does not seem to act in fidelity after exon ligation, as it does in mRNA release, because ATP does not reverse the formation of aberrant mRNA observed in Figure 1b (data not shown) . Thus, Prp22p performs a previously undescribed ATP-dependent proofreading function in splicing at the stage of exon ligation. Prp22p and its role in mRNA release are conserved in humans 53 , suggesting that its role in fidelity is also conserved.
Although the role of Prp22p is unlike those of other fidelity factors, the prp22 suppressors could function similarly to the U6, 5¢ splice site, prp8 and isy1 suppressors. According to a general model for suppression of substrate mutations 18 , the U6, 5¢ splice site, prp8 and isy1 mutants suppress exon-ligation defects by altering an equilibrium between the first and second catalytic conformations of the spliceosome 18, 19, 26 . Specifically, these suppressors destabilize the first catalytic conformation of the spliceosome, thereby suppressing exon-ligation defects by favoring the second catalytic conformation. According to the model, prp22 suppressors could also alter the equilibrium, but by stabilizing the second conformation. In this view, wild-type Prp22p destabilizes the second catalytic conformation. Indeed, Prp22p may be required to establish the equilibrium, promoting retrograde transition from the second catalytic conformation to the first (Fig. 5) , counteracting Prp16p. Prp22p interacts with Prp16p in a two-hybrid analysis 54 , suggesting that these two factors may cooperate to promote the equilibrium. Consistent with a reversible role for Prp22p, rejection of an aberrant intermediate by Prp22p does not commit the intermediate to discard, because aberrant splicing can be derepressed by depleting ATP (Figs. 1 and 4 , and data not shown). Supporting a general role for Prp22p in destabilizing the second catalytic conformation, Prp22p uses ATP to repress exon ligation for a broad range of aberrant intermediates (Figs. 3 and 4) .
In the simplest form of the general equilibrium model, specificity of the spliceosome for a genuine substrate over an aberrant substrate would be determined by the differences in the relative, inherent stabilities of the first and second catalytic conformations. However, a simple equilibrium is not likely to account fully for fidelity in splicing. In other processes, energy is required to discriminate between genuine substrates and similar but incorrect substrates 8 . In splicing, genetic studies have implicated ATP in fidelity 5 . Our biochemical studies have demonstrated directly for the first time a requirement for Figure 5 A dual role for Prp22p in fidelity and mRNA release suggests a proofreading mechanism 7-9 for exon ligation. A simplified splicing pathway is shown. Spliceosome assembly and activation are followed by 5¢ splice-site cleavage, rearrangement of the spliceosome, exon ligation and mRNA release. The rearrangement is shown in two biochemically separable steps 30 proceeding through a putative transitional species (for example, see ref. ATP in repressing aberrant splicing (Figs. 1, 2 and 4) . Furthermore, our studies have revealed that ATP is required to repress splicing of near-consensus 3¢ splice sites but not nonconsensus 3¢ splice sites (Fig. 1) . We propose that Prp22p uses ATP to repress specifically those aberrant intermediates that are competent for catalysis and therefore require an additional inspection beyond binding. We envision two distinct models by which Prp22p could use ATP to enhance fidelity. In either model, Prp22p-mediated rejection could lead either to discard 31, 32 or to resampling of the substrate (Fig. 5) . In the first model, a thermodynamic model, both an aberrant and a genuine substrate are subjected to equilibration between the first and second catalytic conformations (Fig. 5, k rejection 4 k exon ligation ) . In this model, Prp22p could use ATP to destabilize the spliceosome in the second catalytic conformation faster when the spliceosome was bound to aberrant intermediates, thereby enhancing the thermodynamic differences between genuine and aberrant intermediates (compare ref. 9) .
In the second model, a kinetic model, Prp22p functions as a gatekeeper that rejects or accepts a substrate (compare refs. 7,9) . In this model, Prp22p subjects only aberrant substrates to equilibration; Prp22p permits genuine substrates to splice under kinetic control, just as the ribosome permits cognate aminoacyl-tRNA substrates to react under kinetic control 55 . Consistent with kinetic control of a genuine substrate, our own data have revealed no evidence that splicing of a genuine substrate is repressed to any extent by Prp22p (Figs. 2 and 3) . In this kinetic model, the ATP-dependent function of Prp22p competes with exon ligation. In the case of a genuine intermediate, the spliceosome would catalyze exon ligation faster than Prp22p performed its ATP-dependent function, thereby promoting splicing (Fig. 5, k exon ligation 4 k rejection ) . Conversely, in the case of an aberrant intermediate, Prp22p would function faster than the spliceosome catalyzed exon ligation, thereby repressing splicing (Fig. 5, k 56 ). In addition, genuine intermediates bound properly to the spliceosome could repress Prp22p until after exon ligation, when the altered constitution of the substrate might trigger Prp22p-mediated mRNA release. Thus, as a sensor of time or fit, Prp22p could act generally on the second catalytic conformation to promote either fidelity or mRNA release, depending on whether the substrate is at the intermediate or product stage, respectively (Fig. 5) .
Prp22p could promote fidelity and mRNA release as a translocase. The ATP-dependent, 3¢-5¢ translocase activity of Prp22p 38 , which is required for both fidelity (Figs. 3 and 4) and mRNA release 29, 30 , may promote both processes by similar mechanisms. For example, Prp22p may generally translocate along the substrate from the 3¢ exon upstream, disrupting spliceosome interactions with the 3¢ splice site before exon ligation or with the 5¢ exon after exon ligation. Such an activity would lead to rejection of the intermediate or release of the mRNA product, respectively.
Alternatively, Prp22p could function as an ATP-regulated RNAbinding protein. DExD/H-box ATPases bind RNA in a manner that is promoted by ATP 4 . Moreover, the DEAD-box ATPase eIF4AIII, a component of the exon-junction complex (EJC), mediates both ATPdependent assembly of an EJC on RNA and ATP hydrolysis-dependent disassembly of the complex 57 . Further, an EJC component, MAGOH-Y14, inhibits ATP hydrolysis, thereby stabilizing the complex 57 . In analogy to eIF4AIII, Prp22p may facilitate both association of a 3¢ splice site with the spliceosome and, upon ATP hydrolysis, dissociation of the 3¢ splice site, thereby repressing aberrant exon ligation and promoting release of genuine mRNA. Indeed, Pp22p cross-links to the intron just upstream of the 3¢ splice site 39 and recruits distal 3¢ splice sites 30 . In analogy to MAGOH-Y14 (ref. 57) , other fidelity factors, such as Slu7, Prp8 or U5, may regulate the ATPdependent activity of Prp22p, mediating discrimination between genuine and aberrant intermediates. Slu7p is a strong candidate for such a cofactor, given that (i) Slu7p interacts with Prp22p in twohybrid analysis 54 , (ii) Slu7p, like Prp22p, promotes use of distal 3¢ splice sites 27, 58 and (iii) human SLU7 is required to select a positionally correct 3¢ splice site 28 .
The dual role of Prp22p in splicing and fidelity parallels a dual role for the DEAH-box ATPase Prp16p in splicing and fidelity 5, 6 . In particular, both Prp22 and Prp16p are thought to repress splicing of aberrant substrates at an earlier step in splicing than when they promote splicing of genuine substrates. To account for the loss of fidelity in prp16 mutants, it has been reasoned that Prp16p promotes fidelity of branch-site recognition at a stage earlier than when Prp16p promotes spliceosome rearrangements 5 . Through a biochemical analysis of fidelity, we have been able to demonstrate directly that Prp22p discriminates against aberrant substrates before the second transesterification reaction (Fig. 5) , a stage earlier than when Prp22p promotes mRNA release. Thus, by simply acting earlier on aberrant substrates than on genuine substrates, DExD/H-box ATPases in general may proofread the myriad RNA-dependent processes in the cell.
METHODS
Oligonucleotides, plasmids and strains. See Supplementary Methods online.
In vitro splicing. Pre-mRNA substrates were prepared as described 59 . Splicing extracts of S. cerevisiae were prepared using the liquid nitrogen method as described 59 , except that frozen cells were disrupted in a ball mill (MM301, Retsch) for 3 min at 10 Hz for 5 cycles. Splicing reactions 59 containing splicing buffer (3% (w/v) PEG 8000, 2.5 mM MgCl 2 , 60 mM potassium phosphate (pH 7.0)), 40% (v/v) budding yeast extract, 2 mM ATP and 0.4 nM substrate were incubated at 20 1C for 25-30 min. Spliceosomes from TAP-tagged PRP19 extracts were affinity-purified from 200-ml reactions by adding 20 ml of a 50% (w/v) slurry of IgG Sepharose beads (Amersham) that had been washed twice with 1 ml IPP 150 (10 mM Tris (pH 8.0), 0.1% (v/v) NP40, 150 mM NaCl) 60 . Alternatively, spliceosomes from untagged, wild-type PRP22 or mutant prp22 extracts were immunoprecipitated from 100-ml reactions by adding 10 ml of a 50% (w/v) slurry of protein A-Sepharose beads (Sigma) that had been preincubated with 5 ml anti-Ntc20 serum in IPP 500 for 1 h at room temperature and washed twice with 1 ml IPP 150 . In both cases, the reactions were rotated with the bead slurry for 1.5-2 h at 4 1C, washed twice at 4 1C with 1 ml splicing buffer lacking MgCl 2 , then resuspended in 600 ml of the same buffer at 4 1C. Aliquots (50 ml) of immobilized spliceosomes were incubated at 20 1C for 45-60 min with 0.5 mM MgCl 2 with or without 2 mM ATP-MgCl 2 , then stopped and processed as described 59 . NTPs were from Amersham. Exonligation efficiency was calculated as the ratio of mRNA to the sum of mRNA and lariat intermediate; background splicing was calculated from the 'no incubation' lanes. To trap spliceosomes, 250 nM trap oligonucleotide was annealed with 2 nM labeled pre-mRNA in splicing buffer lacking ATP by heating to 65 1C for 3 min in a thermocycler (MJ Research), cooling 1 1C per min to 30 1C and incubating for 5 min at room temperature and then 5 min on ice. One ml of annealed substrate was incubated per 5 ml of splicing reaction for 25-30 min at 20 1C. Then, 50 mM unlabeled substrate was added and incubated for 5 min. Finally, the trap was released by adding 10 mM release oligonucleotide and incubating for 45 min at 20 1C. For reactions containing recombinant protein, TAP-tagged PRP19 extract was supplemented with 2-10 ng of recombinant protein per 5 ml of splicing reaction; splicing reactions and affinity purifications were performed with this supplemented extract as described above.
RT-PCR. See Supplementary Methods.
Primer extension. Wild-type PRP22 and prp22-R805A 42 strains transformed with wild-type or mutated pACT1-CUP1 plasmids were grown in SD-Ura liquid medium at 30 1C to an A 600 of 0.8-1.0 and then total RNA was isolated 59 . RNA (15-50 mg) was analyzed by primer extension 59 using 32 P-radiolabeled ACT1-CUP1 3¢ exon primer oJPS233 (Supplementary Methods) and AMV reverse transcriptase (USB). Reactions were treated with 0.25 M NaOH for 3 min at 90 1C to degrade the RNA, then extracted with phenol/chloroform/ isoamyl alcohol (25:24:1) and ethanol-precipitated. Products were separated on a 6% denaturing polyacrylamide gel and visualized by PhosphorImager (Molecular Dynamics).
Recombinant protein. Recombinant, His 6 -tagged Prp22p and His 6 -tagged Prp43p were expressed and purified as described 44, 45 ; aliquots of peak glycerol-gradient fractions were used in splicing reactions.
Copper growth assay. Wild-type PRP22, prp22-R805A and prp22-G810A cells were transformed with pACT1-CUP1 plasmids, grown at 30 1C in SD-Ura liquid medium to an A 600 of 1.0-1.5 and then diluted. A B25-ml aliquot of each dilution was spotted onto plates containing 0.0 or 0.2 mM CuSO 4 and grown for 3 d at 33 1C (prp22-R805A) or 30 1C (prp22-G810A) 48 .
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
